Alnylam Pharmaceuticals (ALNY) to Release Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY) is scheduled to be announcing its earnings results before the market opens on Thursday, October 31st. Analysts expect the company to announce earnings of ($0.51) per share for the quarter. Alnylam Pharmaceuticals has set its FY 2024 guidance at EPS.Investors interested in registering for the company’s conference call can do so using this link.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. The company’s revenue for the quarter was up 107.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($2.21) EPS. On average, analysts expect Alnylam Pharmaceuticals to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ:ALNY opened at $294.87 on Thursday. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $304.39. The stock has a market capitalization of $37.30 billion, a price-to-earnings ratio of -110.03 and a beta of 0.39. The company’s 50 day simple moving average is $273.47 and its 200 day simple moving average is $220.04.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on ALNY shares. UBS Group raised their price target on shares of Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a “buy” rating in a research note on Friday, June 28th. Raymond James raised their price objective on shares of Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Chardan Capital reissued a “buy” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, October 11th. Stifel Nicolaus increased their price target on Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Thursday, October 10th. Six equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $290.86.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 15,148 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $270.00, for a total value of $4,089,960.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares in the company, valued at approximately $19,829,070. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,148 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $270.00, for a total value of $4,089,960.00. Following the transaction, the chief executive officer now owns 73,441 shares in the company, valued at approximately $19,829,070. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the sale, the director now owns 136 shares in the company, valued at approximately $35,632. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,398 shares of company stock worth $13,595,460 over the last three months. 1.50% of the stock is owned by insiders.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.